Loading...
XHKG
0460
Market cap1.01bUSD
Aug 24, Last price  
0.86HKD
1D
-1.71%
1Q
-15.69%
Jan 2017
-60.19%
IPO
-69.50%
Name

Sihuan Pharmaceutical Holdings Group Ltd

Chart & performance

D1W1MN
XHKG:0460 chart
P/E
37.07
P/S
2.54
EPS
0.02
Div yield, %
1.25%
Shrs. gr., 5y
-0.73%
Rev. gr., 5y
1.22%
Revenues
2.62b
+37.71%
161,776,000286,349,000510,048,000708,907,0001,036,881,0002,242,063,0003,042,531,0004,732,700,0003,084,236,0003,167,211,0003,185,699,0002,745,809,0002,917,405,0002,878,318,0002,464,226,0003,038,391,0002,181,189,0001,860,539,0001,901,109,0002,618,008,000
Net income
180m
P
90,453,000179,266,000237,059,000326,316,000522,065,000824,048,000904,402,0001,303,012,0001,671,281,0002,062,378,0001,708,239,0001,448,935,0001,619,956,000-2,753,332,000473,382,000416,509,000-1,914,918,000-54,017,000-216,662,000179,696,000
CFO
-24m
L
75,980,000182,263,000261,169,000385,648,000380,101,000712,934,0001,046,064,0001,510,633,0001,760,936,0001,568,610,0002,018,026,0001,917,590,0001,792,794,0001,417,858,000227,131,000665,293,00046,493,000199,487,000243,887,000-23,561,000
Dividend
Jun 30, 20260.0109 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Sihuan Pharmaceutical Holdings Group Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. The Medical Aesthetic Products refers to the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetics comprehensive solutions. The company was founded by Feng Sheng Che and Wei Cheng Guo in 2001 and is headquartered in Beijing, China.
URL
http://www.sihuanpharm.com/
IPO date
Oct 28, 2010
Employees
3,241
Domiciled in
CN
Incorporated in
BM

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT